Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: analysis of aggregated data from a systematic literature review.

Date publication

août 2022

Journal

Clinics and research in hepatology and gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi

Tous les auteurs :
Neuzillet C, Malka D, Lièvre A, Khurana IS, Vernerey D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35988887

Résumé

Overall response rate (ORR) and progression-free survival (PFS) are commonly used as endpoints for phase II trials. However, the ultimate goal is to bring survival benefit for the patients. We aimed to assess the correlation between ORR, median PFS and overall survival (OS) using aggregated data from a systematic review of second-line systemic therapies in advanced biliary tract cancer (BTC) patients.

Mots clés

BTC, Biliary Tract Cancer, CI, Confidence Interval, CR, Complete Response, Chemotherapy, cholangiocarcinoma, endpoint, correlation, targeted therapy, FGFR, Fibroblast Growth Factor Receptor, HRQoL, Health-Related Quality of Life, IDH, Isocitrate Dehydrogenase, ORR, Overall Response Rate, OS, Overall Survival, PFS, Progression-Free Survival, PS, Performance Status, RECIST, Response Evaluation Criteria in Solid Tumors, eCCA, Extrahepatic Cholangiocarcinoma, iCCA, Intrahepatic Cholangiocarcinoma

Référence

Clin Res Hepatol Gastroenterol. 2022 08 18;:102010